Compare Campbell Soup Co. (CPB) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Ginkgo Bioworks Holdings Inc — how do they compare? Campbell Soup Co. trades at $19.2 (market cap $5.78B), while Ginkgo Bioworks Holdings Inc trades at $12.95 (market cap $763.64M). The key difference: Campbell Soup Co. is far larger — about 7.6× Ginkgo Bioworks Holdings Inc's market cap, and Campbell Soup Co. pays a 5.16% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and Ginkgo Bioworks Holdings Inc for 7 Days on average.
| CPB | DNA | |
|---|---|---|
Market Cap | $5.78B | $763.64M |
Volume | 11,705,427 | 3,204,177 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $15.83 |
52-Week Low | $18.90 | $5.48 |
Typical Hold Time | 98 Days | 7 Days |
Enterprise Value | $12.83B | $865.59M |
Dividend Yield | 5.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $19.12, up 1.16% on the day, with a bearish technical outlook and mixed analyst sentiment. The company reported a Q4 2026 earnings miss but beat expectations in Q1 and Q2 2026. Recent developments include a 36% dividend cut, a $500 million cost savings program, and workforce reductions. Valuation metrics show a P/E of 14.79 and P/S of 0.6, suggesting potential undervaluation amid operational challenges.
The outlook remains cautious due to margin pressure and declining sales, though cost-cutting initiatives and brand strength in segments like Rao's offer long-term potential. Key risks include execution of turnaround plans and competitive pressures. The consensus price target is $19.73, with most analysts rating Hold.
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
